The proposed GST refund for medical equipment manufacturers addresses a problem that sits deep inside the economics of building factories: tax paid on machinery and external services could remain locked even when the finished product was sold under an inverted duty structure. The recommendation made at the 57th GST Council meeting on October 8 could therefore influence not just manufacturers’ cash flows, but also the pace at which India adds domestic capacity for medical devices.
The Association of Indian Medical Device Industry (AiMeD) has welcomed the proposal, describing it as a response to a demand raised by the industry for several years. However, the recommendation is not yet the same as an operational benefit. The sector is still waiting for the government’s official notification that will establish how the refund mechanism will work in practice.
That distinction matters because the central issue is not simply the rate of GST on a medical device. It is the timing and recoverability of the tax paid while setting up production. A company may incur substantial GST on plant, machinery and professional services before the factory begins generating revenue. If that tax cannot be used or refunded, it becomes a cost tied up in the project rather than a credit available to the business.
## The tax problem behind the recommendation
The source report describes the problem through the example of a company spending Rs 100 crore on a new plant. At an assumed GST rate of 18% on plant and machinery, the tax outgo would be about Rs 18 crore. Under the earlier position described in the report, there was no clear route to use or recover this amount in cases where the inverted duty structure created an accumulation of input tax credit.
An inverted duty structure exists when inputs attract a higher tax burden than the finished product. In that situation, a manufacturer can accumulate credit because the tax paid while buying inputs and services is higher than the tax collected on the final output. The gap can remain on the company’s books and affect working capital, particularly during an expansion phase when the business is already spending heavily on land, buildings, equipment and commissioning.
For medical-device manufacturers, the problem can extend beyond machinery. The report says GST paid on services such as consultancy, marketing and security could also remain blocked. These services may not become part of the physical product, but they are connected to setting up and operating the manufacturing business. When the associated tax cannot be recovered promptly, the effective cost of establishing capacity rises.
The proposed change would allow refunds of input tax credit accumulated on capital goods and input services in sectors facing an inverted duty structure. The stated objective is to prevent taxes paid during investment and production from becoming a permanent or long-term cash-flow burden.
## Why cash flow matters more than the headline rate
The significance of the recommendation lies in the difference between a tax liability and a cash-flow blockage. A business can theoretically recover a tax credit at a later stage and still face pressure today if the money remains unavailable while it is building capacity. For a manufacturer, that affects how much capital is required to complete a plant, purchase equipment and sustain operations before sales expand.
AiMeD forum coordinator and Hindustan Syringe and Medical Devices managing director Rajiv Nath said the reform corrects what he described as a major flaw in the tax system. According to the report, Nath said domestic manufacturers had earlier carried a heavy tax burden on machinery and essential business services, and welcomed the proposed route to recover the blocked tax.
The industry body’s response also shows why the measure is being presented as a manufacturing intervention rather than only a compliance change. If the refund is processed with reasonable speed and predictable rules, companies may have more cash available for additional equipment, production lines and new facilities. If the process remains slow or uncertain, the formal entitlement may not translate into the same level of operational relief.
The council has also recommended that 90% of provisional refunds for inverted-duty and export-related claims be approved automatically on the basis of risk assessment, without requiring officer intervention. This is intended to move the process towards a system-led model. Its effectiveness will depend on the final notification, the risk parameters and the way claims are examined after provisional payment.
## The manufacturing and import-substitution question
Medical devices occupy an important position in the built and industrial systems that support healthcare. Hospitals and clinics depend on a reliable supply of equipment, while manufacturers need production facilities, specialised machinery and supply chains capable of meeting demand. A tax structure that makes domestic production more expensive or less liquid can influence whether companies expand locally or rely more heavily on imports.
The report says AiMeD expects the proposed reform to encourage companies to establish more plants in India and expand production capacity. That is an industry expectation, not yet a measured outcome. The immediate fact established by the report is that the association believes the change could improve the investment environment by reducing the amount of tax locked into capital expenditure and outsourced services.
The Rs 100-crore example illustrates the scale at which the issue can become significant. An Rs 18-crore tax component may not represent the full cost of a manufacturing project, but it can materially affect the amount of working capital available during construction and commissioning. For smaller or growing manufacturers, the timing of recovery may be as important as the total amount recovered.
This also places the proposal within the wider effort to strengthen domestic manufacturing. The report links the measure to the government’s Make in India objective and to the possibility of making Indian producers more competitive in global markets. The evidence supplied does not establish how many companies will claim refunds, how much revenue will be involved or how much new capacity could result. Those questions will require implementation data after the notification and subsequent claims are processed.
## The implementation gap remains decisive
The most important uncertainty is administrative. The GST Council has made recommendations, but the report states that the medical-device industry is awaiting an official notification. Until that notification is issued, manufacturers may not know the precise eligibility conditions, documentation requirements, claim period, treatment of different categories of capital goods or timelines for receiving refunds.
This is where the institutional design of the reform will determine its practical value. A refund available only after lengthy scrutiny may continue to tie up capital. A risk-based system can reduce administrative contact and accelerate provisional payments, but it must still define how risk is assessed and how disputed claims are handled. The report does not provide those operational details.
The council’s recommendation on automatic provisional refunds is therefore significant, but it should not be read as proof that every eligible company will immediately receive money. The final rules will determine whether the system is predictable enough for companies to factor the refund into project planning and working-capital decisions.
The proposal also raises a broader governance issue in tax administration: whether a policy benefit is judged by its legal availability or by the speed and certainty with which businesses can access it. For manufacturing projects, delays can affect equipment purchases, commissioning schedules and the ability to move from investment to production. The source material does not provide evidence on current processing times, so the effect of the new mechanism cannot yet be quantified.
## A related change for pharmaceutical companies
The GST Council has also recommended clarity on input tax credit treatment when expired medicines and healthcare products are written off and legally destroyed. The report says this could provide relief to pharmaceutical companies dealing with inventory that can no longer be sold.
This measure addresses a different point in the product cycle. The medical-device proposal concerns tax accumulated during investment and production, while the pharmaceutical provision concerns products that have reached the end of their usable or saleable life. Both involve the treatment of input tax credit when the original commercial value of a product or investment is disrupted.
The supplied report does not specify the exact wording of the proposed clarification or the categories of products covered. The practical effect will therefore depend on the official rules and on how companies document expiry, destruction and write-off. It remains important to distinguish the council’s recommendation from a final, enforceable notification.
The GST Council’s decision is best understood as an attempt to remove a tax-related barrier from the early stages of industrial expansion. For medical-device manufacturers, the potential benefit is a release of cash locked in machinery and service-related credits. For policymakers, the test will be whether that relief reaches factories without creating a new layer of uncertainty or delay.
The evidence currently confirms the industry’s response, the proposed refund principle and the planned move towards risk-based provisional refunds. It does not yet confirm the final legal framework, the number of beneficiaries or the investment and production gains that may follow. The next milestone is the government’s official notification, followed by the way manufacturers are able to file and receive claims under the new system.
